ReviewInflammation2017
Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases.
Review in Inflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Semaphorin-3A in autoimmune rheumatic diseases: immunological and pathological aspects.Inflammopharmacology · 2025Review
- Reduced circulating interleukin 35 is associated with enhanced peripheral T cell function in primary biliary cholangitis.Biomolecules & biomedicine · 2023Article
- Stem cell therapies for autoimmune hepatitis.Stem cell research & therapy · 2021Review
- Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma.Clinical and experimental immunology · 2021Article
- Urine and serum interleukin 35 as potential biomarkers of lupus nephritis.Central-European journal of immunology · 2021Article
- Pathogenesis and Function of Interleukin-35 in Rheumatoid Arthritis.Frontiers in pharmacology · 2021Review
- Association between Interleukin 35 Gene Single Nucleotide Polymorphisms and Systemic Lupus Erythematosus in a Chinese Han Population.Biomolecules · 2019Article
- Mesenchymal stem cells overexpressing IL-35: a novel immunosuppressive strategy and therapeutic target for inducing transplant tolerance.Stem cell research & therapy · 2018Review
- Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis.Rheumatology international · 2018Article
- Emerging role of semaphorin-3A in autoimmune diseases.Inflammopharmacology · 2018Review
- IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells.Journal of cellular and molecular medicine · 2018Article
- Lower level of IL‑35 and its reduced inhibition in Th17 cells in patients with bone marrow mononuclear cells Coombs test‑positive hemocytopenia.Molecular medicine reports · 2018Article
- Article
- Mechanisms of Tolerance Induction by Dendritic CellsFrontiers in immunology · 2018Review
- IL-35 may maintain homeostasis of the immune microenvironment in periodontitis.Experimental and therapeutic medicine · 2017Article
- IL-35 Pretreatment Alleviates Lipopolysaccharide-Induced Acute Kidney Injury in Mice by Inhibiting NF-κB Activation.Inflammation · 2017Article
- Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease.Mediators of inflammation · 2017Review
- Interleukin-35 mitigates the function of murine transplanted islet cells via regulation of Treg/Th17 ratio.PloS one · 2017Article
- Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection.Frontiers in cellular and infection microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune diseases contain a large number of pathologies characterized by various factors that contribute to a breakdown in self-tolerance. Cytokine-mediated immunity plays an essential role in the pathogenesis of varieties of autoimmune diseases. Recent studies reveal that interleukin-35 (IL-35), a newly identified cytokine of IL-12 family, is implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), etc. In this review, we will discuss the biological features of IL-35 and summarize recent advances in the role of IL-35 in the development and pathogenesis of autoimmune diseases; the discoveries gained from these findings might translate into future therapies for these diseases.
Indexed as
Identifiers
27696334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.